Regulatory considerations for the development of autologous induced pluripotent stem cell therapies
- PMID: 20632860
- DOI: 10.2217/rme.10.55
Regulatory considerations for the development of autologous induced pluripotent stem cell therapies
Abstract
Induced pluripotent stem (iPS) cells offer tremendous opportunity for the creation of autologous cellular therapies, in which gene correction or the avoidance of immune response issues are desirable. In addition, iPS cells avoid the ethical concerns raised by the sourcing of human embryonic stem cells (hESCs) from embryos. iPS cells share many characteristics with hESCs and it is anticipated that existing experience with hESCs will translate to rapid progress in moving iPS cell-derived products toward clinical trials. While the potential clinical value for these products is considerable, the nature of current manufacturing paradigms for autologous iPS cell products raises considerable regulatory concerns. Here, the regulatory challenges posed by autologous iPS cell-derived products are examined. We conclude that there will be considerable regulatory concerns primarily relating to reproducibility of the manufacturing process and safety testing within clinically limited time constraints. Demonstrating safety of the final cell product in an autologous setting will be the single greatest obstacle to progressing autologous iPS cell-based therapies into the clinic.
Similar articles
-
Translational prospects for human induced pluripotent stem cells.Regen Med. 2010 Jul;5(4):509-19. doi: 10.2217/rme.10.39. Regen Med. 2010. PMID: 20632855 Review.
-
Commercialization challenges associated with induced pluripotent stem cell-based products.Regen Med. 2010 Jul;5(4):593-603. doi: 10.2217/rme.10.50. Regen Med. 2010. PMID: 20632862
-
Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.Biotechnol Adv. 2013 Dec;31(8):1600-23. doi: 10.1016/j.biotechadv.2013.08.009. Epub 2013 Aug 17. Biotechnol Adv. 2013. PMID: 23962714 Review.
-
Regulatory considerations for pluripotent stem cell therapies.Prog Brain Res. 2017;230:151-163. doi: 10.1016/bs.pbr.2016.12.008. Epub 2017 Mar 7. Prog Brain Res. 2017. PMID: 28552227 Review.
-
Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.Bioethics. 2013 Feb;27(2):89-96. doi: 10.1111/j.1467-8519.2011.01896.x. Epub 2011 Jul 4. Bioethics. 2013. PMID: 21726264
Cited by
-
Founder's award to Antonios G. Mikos, Ph.D., 2011 Society for Biomaterials annual meeting and exposition, Orlando, Florida, April 13-16, 2011: Bones to biomaterials and back again--20 years of taking cues from nature to engineer synthetic polymer scaffolds.J Biomed Mater Res A. 2011 Sep 1;98(3):323-31. doi: 10.1002/jbm.a.33154. Epub 2011 Jun 28. J Biomed Mater Res A. 2011. PMID: 21714068 Free PMC article. Review.
-
Regulation of stem cell-based therapies in Canada: current issues and concerns.Stem Cell Rev Rep. 2012 Sep;8(3):623-8. doi: 10.1007/s12015-012-9360-0. Stem Cell Rev Rep. 2012. PMID: 22410974
-
Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.Nat Biotechnol. 2014 Aug;32(8):724-6. doi: 10.1038/nbt.2973. Nat Biotechnol. 2014. PMID: 25093882 No abstract available.
-
Distinct Metabolic States Can Support Self-Renewal and Lipogenesis in Human Pluripotent Stem Cells under Different Culture Conditions.Cell Rep. 2016 Aug 9;16(6):1536-1547. doi: 10.1016/j.celrep.2016.06.102. Epub 2016 Jul 28. Cell Rep. 2016. PMID: 27477285 Free PMC article.
-
Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining.Mutat Res. 2011 Aug 1;713(1-2):8-17. doi: 10.1016/j.mrfmmm.2011.05.018. Epub 2011 Jun 28. Mutat Res. 2011. PMID: 21718709 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
